Pricing drugs, selling hype and how we got here in the first place
May 15, 2018 - 15:46
Radio and PodcastLive Radio & Podcasts
Science & Medicine
Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place
In an episode free of Valeant Pharmaceuticals and Martin Shkreli, Fierce editors discuss a Senate investigation into Gilead Sciences' pricing of the hepatitis C drug Sovaldi, BioMarin's efforts to win approval for a rare...
Related Episodes
Continue listening to more episodes from FierceBiotech Radio.
